Core Viewpoint - The article discusses the positive impact of the Federal Reserve's interest rate cut on the innovative pharmaceutical industry, highlighting the potential for increased investment and growth in the sector [1]. Market Performance - On September 22, the Shanghai Composite Index opened up by 0.05%, while the ChiNext Index rose by 0.1% [1]. - The cobalt sector saw a strong performance, and the IPO of Moer Thread is set to take place this week, leading to a collective surge in related stocks [1]. - Conversely, the robotics sector experienced a continuous pullback, with declines in the optical chip and oil and gas sectors [1]. Federal Reserve's Interest Rate Cut - The Federal Reserve announced a 25 basis point interest rate cut on September 2025, marking its first cut of the year [1]. - Historical trends indicate that interest rate cuts typically benefit the innovative pharmaceutical sector [1]. Investment Environment - The long development cycles and significant funding needs of innovative drug research suggest that a recovering global financing environment may enhance investment activity in the pharmaceutical industry [1]. - Past interest rate cut cycles have shown a general upward trend in the global biopharmaceutical sector, indicating significant elasticity [1]. - The biopharmaceutical sector in the A-share market has historically performed well during bull market conditions [1]. Recent Developments - Jinfang Pharmaceutical was listed on the Hong Kong Stock Exchange on September 19, 2025, becoming a focal point in the Hong Kong 18A sector [1]. - The company raised $268 million, setting a new high for the sector since 2022, with cornerstone investors subscribing for $100 million, also the highest since 2022 [1]. Future Outlook - In the short term, improved liquidity and market sentiment may drive a valuation recovery in the innovative pharmaceutical sector [1]. - In the long term, lower financing costs are expected to support corporate research and international collaboration, fostering innovation and high-quality development in the industry [1]. - The biopharmaceutical sector has historically performed exceptionally well in environments characterized by interest rate cuts and bull markets [1].

Group 1 - The non-ferrous cobalt concept is showing strong performance across the board, while the consumption electronics sector is active, and the robotics and oil and gas sectors are experiencing declines [1][2] - The A-share market opened with all three major indices rising: Shanghai Composite Index up 0.05%, Shenzhen Component Index up 0.37%, and ChiNext Index up 0.10% [1][2] Group 2 - The Hong Kong stock market opened with the Hang Seng Index down 0.32% and the Hang Seng Tech Index down 0.68%, with notable declines in Kuaishou, which fell over 6% due to an investigation into its e-commerce operations [3] - Pharmaceutical stocks generally rebounded, with Nocera Healthcare rising over 3%, while Hongteng Precision opened nearly 7% higher, approaching historical highs [3] Group 3 - Anta Sports saw a decline of over 4% following an apology related to a sponsorship incident involving fireworks in the Himalayas [4][5]

Group 1 - The non-ferrous cobalt concept is showing strong performance across the board, while the consumption electronics sector is active, and the robotics and oil & gas sectors are experiencing declines [1][3] - The A-share Apple supply chain is active at the opening, with Luxshare Precision hitting the daily limit, and several other stocks such as GoerTek, Darui Electronics, Lens Technology, and others opening high [1] - The Hong Kong stock market opened with the Hang Seng Index down 0.32% and the Hang Seng Tech Index down 0.68%, with notable declines in Kuaishou and Anta Sports [4] Group 2 - The A-share market opened with all three major indices rising slightly, with the Shanghai Composite Index up 0.05%, the Shenzhen Component Index up 0.37%, and the ChiNext Index up 0.10% [2][3] - The People's Bank of China conducted a 240.5 billion yuan 7-day reverse repurchase operation at an interest rate of 1.40%, along with a 300 billion yuan 14-day reverse repurchase operation [5]